AI Drug Discovery and Digital Assets Reshape Hong Kong's Small-Cap Landscape

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Hong Kong's small-cap market is undergoing a quiet transformation as companies pivot toward technology-driven growth. Viva Biotech (1873.HK) saw its shares jump over 23% on October 6 following an AI-powered reverse target discovery collaboration with XDYY, with AI-related projects now accounting for 14% of CRO revenue. OSL Group (0863.HK) has become a digital asset pioneer, completing Hong Kong's inaugural HKDAP stablecoin transaction in September and securing a new mandate for USDGO-based fund services in early October, driving 30.4% year-on-year revenue growth in 2025.

Traditional sectors are adapting through strategic shifts. Befar Group (6745.HK) is expanding its electronic chemicals portfolio with 6N-grade high-purity chlorine projects, while Comba Telecom (2342.HK) navigates volatility in optical communications despite year-to-date declines exceeding 50%. In biopharma, LongBio Pharma (2667.HK) advanced its anti-IgE monoclonal antibody LP-003 to BLA submission stage with China's NMPA, marking its first 自主研发 drug candidate to reach this milestone.

Corporate governance changes are accelerating. Baige Digital (1779.HK) approved converting 170 million domestic shares to H-shares, and I.CENTURY Holding (8507.HK) rebranded as China Ecological Land Management to focus on renewable energy. Power Assets (0006.HK) executed major portfolio restructuring, selling UK power assets to Engie while increasing Canadian oil sands exposure through Cenovus Energy.

JST GROUP (2672.HK) turned profitable with growth approaching 260% in adjusted net profit, contrasting with TongrentangCare (6687.HK)'s lackluster debut. Market reactions remain mixed, as LongBio Pharma dropped nearly 30% in the week following its Stock Connect inclusion, underscoring investor caution toward unprofitable biotech firms.

Source: Global Report The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.